BTG Specialty Pharmaceuticals
BTG Specialty Pharmaceuticals, a US-based subsidiary of SERB Pharmaceuticals, develops and commercialises life-saving antidotes and oncology supportive-care medicines—including Voraxaze (glucarpidase)—for hospitals, emergency responders, and government preparedness agencies worldwide.
- Company typePrivate
- Founded1940
- HeadquartersConshohocken, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What BTG Specialty Pharmaceuticals does
BTG Specialty Pharmaceuticals is a US-headquartered subsidiary of the UK-based private pharmaceutical group SERB Pharmaceuticals, developing, manufacturing and commercialising life-saving antidotes and supportive-care medicines used in hospital and emergency-care settings. The company's defining product is Voraxaze (glucarpidase), a specialty biologic indicated for the reduction of toxic plasma methotrexate concentrations in patients with renal impairment—an oncology supportive-care use case anchored at the Conshohocken, Pennsylvania base. The BTG® trademark is a registered identity of Protherics Medicines Development Ltd and is operated as a distinct brand within the broader SERB portfolio of 70+ essential medicines spanning antidotes, critical care, and emergency countermeasures.
The business model is that of a specialty pharmaceutical operator generating revenue from direct sales of branded, often orphan-indication therapeutics to hospital systems, oncology care providers, emergency preparedness agencies, first responders, and non-profit organisations. Distribution leverages SERB's integrated infrastructure covering 100+ countries with direct sales presence in 18, including channels to government agencies and CBRN preparedness networks. Within SERB, BTG functions as the recognised US oncology-supportive and antidote brand, gaining the upside of shared regulatory, manufacturing, and clinical-development capabilities while contributing to SERB's broader emergency-medicines franchise.
Commercially, the firm pursues brand and portfolio expansion both organically—illustrated by the May 2026 US launch of ThyroSafe 130mg potassium iodide tablets—and inorganically, demonstrated by SERB's €115M May 2026 acquisition of EU/UK/MENA rights to Idefirix (imlifidase) from Hansa Biopharma, and by the January 2026 appointment of Dr Peter C. Adamson to the US Board to deepen oncology-development governance. Revenue mechanics rest on per-treatment / per-vial pricing of high-value, low-frequency-use hospital products rather than high-volume primary-care scripts, with pricing not publicly disclosed.
BTG Specialty Pharmaceuticals firmographics
Firmographics- Name
- BTG Specialty Pharmaceuticals
- Legal name
- Protherics Medicines Development Ltd
- Website
- https://btgsp.com
- Company type
- Private
- Founded year
- 1940
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- BTG Specialty Pharmaceuticals, a US-based subsidiary of SERB Pharmaceuticals, develops and commercialises life-saving antidotes and oncology supportive-care medicines—including Voraxaze (glucarpidase)—for hospitals, emergency responders, and government preparedness agencies worldwide.
- Ownership category
- akta.pro rank
BTG Specialty Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)
Keywords
Where BTG Specialty Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Conshohocken
- HQ country
- United States
- HQ region
- North America
Markets served
BTG Specialty Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Distribution channels3 records
BTG Specialty Pharmaceuticals product offering
Product offeringCore offering
BTG Specialty Pharmaceuticals develops, manufactures, and commercializes life-saving specialty pharmaceuticals used in hospitals and emergency care settings. Its portfolio centers on antidotes and supportive care medicines for complex and life-threatening conditions, including Voraxaze (megludase/glucarpidase) for methotrexate toxicity management and ThyroSafe potassium iodide tablets for thyroid protection. Products are supplied to healthcare providers in over 100 countries under the BTG® brand within the SERB Pharmaceuticals group.
Product overview
BTG Specialty Pharmaceuticals operates as part of SERB Pharmaceuticals' portfolio, focusing on rare diseases and medical emergencies. The company's key product is Voraxaze (megludase/glucarpidase), a specialized pharmaceutical for methotrexate toxicity management in cancer patients. BTG products are part of SERB's broader portfolio of 70+ essential medicines, antidotes, and critical care treatments distributed to healthcare providers in over 100 countries. BTG® is a registered trademark of Protherics Medicines Development Ltd.
Differentiator
Problem solved
Functional benefit
Products and services
- Voraxaze (megludase/glucarpidase) A specialized pharmaceutical product used in oncology care settings to reduce toxic methotrexate levels in patients with renal impairment, addressing methotrexate toxicity management as a cancer treatment complication.
- ThyroSafe 130mg Potassium Iodide Tablets Potassium iodide tablets commercially available in the US in a 130mg dose, used for thyroid protection in radiation emergencies as part of SERB's emergency medicine portfolio including medical countermeasures for CBRN threats.
Companies that use BTG Specialty Pharmaceuticals
Customer profileSegments4 records
Ideal customer profiles3 records
BTG Specialty Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BTG Specialty Pharmaceuticals partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights5 records
BTG Specialty Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Helsinn Group: Privately-held specialty pharma focused on oncology supportive care and cancer therapeutics. Compares closely to BTG on customer base (oncology care providers), product focus (supportive-care/antiemetic/antidote adjacencies), and global specialty distribution.
- Emergent BioSolutions: Specialty biopharmaceutical company focused on CBRN medical countermeasures and specialty therapeutics (incl. antidote products). Directly comparable to BTG in serving the same government/health-system buyers for emergency preparedness and overdose/toxicology antidotes.
- Swedish Orphan Biovitrum (Sobi): Specialty biopharma dedicated to rare diseases and specialty care, with growing oncology supportive-care adjacencies. Comparable business model and customer type (hospital and specialty pharmacies) to BTG Specialty Pharmaceuticals.
- Kedrion Biopharma: Specialty plasma-derived and rare-disease biopharma that includes an antidotes/toxin-neutralisation portfolio. Comparable in manufacturing specialty biologics for critical-care and emergency use, with hospital and emergency-preparedness distribution.
- Recordati Rare Diseases: Specialty pharma arm of Recordati focused on rare and serious conditions, distributing via specialty and hospital channels. Closely parallel to BTG in rare-disease specialty pharma model, target prescribers, and global commercial reach.
- Meridian Medical Technologies: Developer and manufacturer of auto-injector antidotes used against chemical-warfare nerve agents and organophosphate poisoning. Highly comparable to BTG's antidote portfolio in product form, end-users (military/emergency preparedness), and regulatory pathway.
Broad incumbents
- Mallinckrodt Pharmaceuticals: Specialty pharma with hospital-focused portfolio spanning critical care, antidotes, and rare diseases. Wider portfolio than BTG but overlaps directly in specialty injectables/antidote categories and hospital channel sales.
- Jazz Pharmaceuticals: Specialty pharma with oncology supportive care and CNS franchises, selling to hospital and specialty providers. Broader portfolio but overlapping hospital-channel specialty model and oncology/critical-care customer overlap with BTG.
- GSK (Specialty / Established Pharma): Global pharma with relevant adjacencies in oncology supportive care and emergency medicines. Not a direct antidotes competitor but serves the same hospital and government preparedness customer base with comparable specialty distribution capabilities.
- Pfizer (Hospital / Injectables): Large incumbent pharma whose hospital/sterile injectables business (formerly Hospira) competes broadly with BTG in injectable antidotes and critical-care injectables. Comparable in product format and end-buyer, though much broader portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
BTG Specialty Pharmaceuticals social profiles
Digital presenceBTG Specialty Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
BTG Specialty Pharmaceuticals leadership team
Management profileNumber of profiles
BTG Specialty Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BTG Specialty Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BTG Specialty Pharmaceuticals
What does BTG Specialty Pharmaceuticals do?
BTG Specialty Pharmaceuticals develops, manufactures, and commercializes life-saving specialty pharmaceuticals used in hospitals and emergency care settings. Its portfolio centers on antidotes and supportive care medicines for complex and life-threatening conditions, including Voraxaze (megludase/glucarpidase) for methotrexate toxicity management and ThyroSafe potassium iodide tablets for thyroid protection. Products are supplied to healthcare providers in over 100 countries under the BTG® brand within the SERB Pharmaceuticals group.
Is BTG Specialty Pharmaceuticals a public or private company?
BTG Specialty Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was BTG Specialty Pharmaceuticals founded?
BTG Specialty Pharmaceuticals was founded in 1940. It employs 251 to 500 people.
Where is BTG Specialty Pharmaceuticals based?
BTG Specialty Pharmaceuticals is headquartered in Conshohocken, United States, in the North America region.
Who are BTG Specialty Pharmaceuticals's main competitors?
Direct peers on record are Helsinn Group, Emergent BioSolutions, Swedish Orphan Biovitrum (Sobi), Kedrion Biopharma, Recordati Rare Diseases and Meridian Medical Technologies. Broad incumbents are Mallinckrodt Pharmaceuticals, Jazz Pharmaceuticals, GSK (Specialty / Established Pharma) and Pfizer (Hospital / Injectables).
Does BTG Specialty Pharmaceuticals have an API?
No public API is recorded for BTG Specialty Pharmaceuticals.
What industry is BTG Specialty Pharmaceuticals in?
BTG Specialty Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories. Its NAICS code is 325412 and its SIC code is 2834.